30947 results about "Pharmacology" patented technology

The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).

Provided herein are compounds having the following structure (I), wherein the substituents are as defined herein, compositions comprising a compound, and methods for modulating the activity of KRAS G12D and / or G12V.

This disclosure provides cyclic peptide compounds of formula (A) or formula (II) as inhibitors of Ras kinase, and compositions and use of the same in treating diseases associated with Ras kinase.

The present disclosure relates to a pharmaceutically acceptable salt of a G12D inhibitor compound and a crystal form thereof. Specifically, provided in the present disclosure are a salt of 2-amino-4-((5S,5aS,6S,9R)-12-((1-((4-(difluoromethylene)piperidin-1-yl)methyl)cyclopropyl)methoxy)-1-fluoro-5-methyl-5a,6,7,8,9,10-hexahydro-5H-4-oxa-3,10a,11,13,14-pentaaza-6,9-methanonaphtho[1,8-ab]cyclohepten-2-yl)-7-fluorobenzo[b]thiophene-3-carbonitrile and a crystal form thereof.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat anxiety disorders, eating disorders, and headache disorders.

The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

Compound (I), deuterated derivatives, and pharmaceutically acceptable salts of any of the foregoing are disclosed. Methods of treating cystic fibrosis using these compounds are also disclosed.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

The invention relates to the technical field of biology, in particular to multifunctional belly-expanding hippocampal peptide as well as a preparation method and application thereof. Comprising a polypeptide with an amino acid sequence as shown in SEQ ID NO.1. The hippocampus antioxidative peptide is prepared by adopting an ultrahigh pressure pretreatment and enzymolysis technology, the adopted extraction process is simple in route, and the time and the production cost are effectively saved; an animal model is utilized to prove the anti-oxidation effect and the effect of improving male reproductive disorder and testis injury of the multifunctional belly-expanding hippocampal peptide; and on the basis, a novel peptide fragment with high activity, no toxicity and no sensitization is obtained.

A device, including an electrode array carrier, that carries one or more electrode arrays, and a therapeutic substance such as for example an anti-inflammatory, wherein the therapeutic substance is located in at least one cavity of the carrier, the cavity having at least one of a non-uniform depth or a non-uniform width with respect to location in a direction of the depth that has an effective impact on a delivery of the therapeutic substance to a human.

The disclosure provides methods for treating a subject in need thereof comprising administering to the subject a therapeutically-effective dose of psilocybin. The methods described herein may be used to treat a variety of diseases, disorders, and conditions. For example, the methods may be used to treat neurocognitive disorders (e.g., Alzheimer's disease, Parkinson's disease), ADHD, Epilepsy, Autism, Sleep-wake disorders, Chronic pain, Inflammatory Disorders, IBD, Stroke, ALS, and / or Multiple Sclerosis.

The invention discloses a hydroxytyrosol-ergothioneine eutectic crystal as well as a preparation method and application thereof, and belongs to the technical fields of medicines, foods, daily chemicals and the like. The invention provides a hydroxytyrosol-ergothioneine eutectic crystal. The X-ray powder diffraction pattern of the hydroxytyrosol-ergothioneine eutectic crystal has characteristic diffraction peaks at least corresponding to the positions where the 2 theta value is 4.21 degrees + / -0.2 degrees, 8.36 degrees + / -0.2 degrees, 12.29 degrees + / -0.2 degrees, 15.29 degrees + / -0.2 degrees, 19.40 degrees + / -0.2 degrees, 20.98 degrees + / -0.2 degrees, 23.12 degrees + / -0.2 degrees and 28.73 degrees + / -0.2 degrees. According to the hydroxytyrosol-ergothioneine eutectic, the melting point of hydroxytyrosol is increased, the hygroscopicity of hydroxytyrosol is remarkably reduced, and meanwhile the stability of hydroxytyrosol and ergothioneine is enhanced. In addition, after the ergothioneine hydroxytyrosol forms the eutectic crystal, the ergothioneine hydroxytyrosol can also play better anti-oxidation and anti-aging effects.

The invention provides aqueous ophthalmic solutions of phentolamine or pharmaceutically acceptable salts thereof, medical kits, and methods for using such ophthalmic solutions to improve visual performance in a patient. Exemplary aqueous ophthalmic solutions include those containing phentolamine mesylate, mannitol, sodium acetate, and water.

The disclosure provides methods for treating a patient in need thereof comprising co-administering to the patient a therapeutically-effective dose of psilocybin and one or more benzodiazepines. The present disclosure also provides methods to reduce the SSRI washout period in patients prior to administration of psilocybin therapy.

Disclosed are a pentapeptide compound and a composition and use thereof, relating to the technical field of polypeptides, the peptide or a salt thereof having a structure as shown in formula (I): R1-Lys-Lys-Leu-Ala-R2 (I). The invention also relates to a cyclic peptide, and the structure of the cyclic peptide is Cyclo-[Lys-Lys-Lys-Leu-Ala]. The compound disclosed by the invention has the effects of controlling oil, repairing, resisting oxidation and the like, and can be used for nursing skin or mucosa.

The present disclosure relates generally to polymorphic forms of a KRAS inhibitor, and more specifically to polymorphic forms of a pyridopyrimidine derivative, and uses thereof.

The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as cancer. The compounds are contemplated to be modulators of Ras (e.g., K-Ras).

Methods for treating or preventing asthma (e.g., allergic asthma, asthma associated with allergic bronchopulmonary aspergillosis (ABPA), moderate-to-severe asthma, persistent asthma or the like) and associated conditions (e.g., ABPA, ABPA comorbid with asthma, ABPA comorbid with cystic fibrosis (CF), ABPA comorbid with asthma and CF) in a subject are provided. Methods comprising administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4R) antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof, are provided.

The invention discloses a ginseng exosome, an extraction method thereof and application of the ginseng exosome in preparation of anti-photoaging skin care products, and belongs to the technical field of biological medicines. In order to solve the technical blank of ginseng exosomes in the aspect of light aging resistance in the prior art and solve the technical problems of complicated steps, long time consumption and small treatment capacity of exosome extraction by an ultracentrifugation method in the prior art, the invention provides an extraction method of ginseng exosomes. Therefore, the extraction rate of the ginseng exosome is improved, the treatment steps are simplified, the time is saved, and the purpose of producing the ginseng exosome in a large scale is achieved. The ginseng exosome obtained through the extraction method can be applied to preparation of anti-photoaging skin care products, and clinical application of the exosome is achieved.

The invention provides a pyrimidino heterocyclic compound as well as a pharmaceutical composition and application thereof. The invention provides a pyrimidino heterocyclic compound as shown in a formula I, and a stereoisomer, a tautomer, an atropisomer or a pharmaceutically acceptable salt of the pyrimidino heterocyclic compound. The compound disclosed by the invention has good proliferation inhibition activity on NCI-H358 cells, AsPC-1 cells and Capan-1 cells containing KRAS mutation, and has relatively weak proliferation inhibition activity on PC-9 cells wild in KRAS. # imgabs0 #

The invention provides an intracranial neuron electrical stimulation system for treating epilepsy and other brain diseases involving epileptic seizure, which can immediately apply intracranial neuron electrical stimulation to the interseizure epilepsy activity in a personalized manner after detecting the interseizure epilepsy pattern each time. And the stimulation is activated by intracranial electroencephalogram (EEG) detection. The intracranial stimulation for epileptic activities in the epileptic seizure period continuously acts along with time, the forming process of an epileptic network can be blocked, the neuronal super-synchronization risk is reduced, and therefore the control effect on epileptic seizure is improved. The invention also includes the use of nerve adjustment biomarkers, thereby dynamically optimizing the detectability and providing more accurate overall assessment for the patient's treatment progress. Finally, according to the scheme, by detecting the intracranial EEG mode and the high-risk state mode (such as the epileptic state and the sudden accidental death risk in epilepsy) in the attack period, an instant alarm is given to the patient / nursing personnel, and it is ensured that safe treatment measures are taken for the patient in time.

Disclosed herein are polynucleic acid molecules, pharmaceutical compositions, and methods for treating muscle dystrophy (DM1).

Pharmaceutically active benzofuran compositions for the treatment of mental disorders or for mental enhancement, including for entactogenic therapy. The present invention also includes benzofuran compounds, compositions, and methods for generally modulating central nervous system activity and treating central nervous system disorders.

This invention relates to the large-scale production of psilocybin for use in medicine. More particularly, it relates to a method of obtaining high purity crystalline psilocybin, particularly, in the form of Polymorph A. It further relates to a method for the manufacture of psilocybin and intermediates in the production thereof and formulations containing psilocybin.

The present disclosure provides methods of treating pulmonary fibrosis, the methods comprising administering taladegib to a subject in need thereof.